10,716 Shares of DaVita Inc. $DVA Purchased by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of DaVita Inc. (NYSE:DVA) during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm purchased 10,716 shares of the company’s stock, valued at approximately $1,874,000.

A number of other large investors have also bought and sold shares of the stock. CoreCap Advisors LLC increased its stake in shares of DaVita by 161.7% in the third quarter. CoreCap Advisors LLC now owns 157 shares of the company’s stock worth $27,000 after buying an additional 97 shares during the period. Western Wealth Management LLC purchased a new position in shares of DaVita during the 1st quarter worth approximately $60,000. Compass Financial Management LLC bought a new stake in shares of DaVita during the second quarter valued at approximately $72,000. Summit Securities Group LLC boosted its position in shares of DaVita by 852.8% during the first quarter. Summit Securities Group LLC now owns 505 shares of the company’s stock valued at $78,000 after purchasing an additional 452 shares in the last quarter. Finally, Cassaday & Co Wealth Management LLC bought a new stake in shares of DaVita during the first quarter valued at approximately $79,000. 90.12% of the stock is owned by hedge funds and other institutional investors.

DaVita Stock Performance

NYSE:DVA opened at $191.27 on Friday. The firm has a market cap of $12.03 billion, a P/E ratio of 14.08, a P/E/G ratio of 0.48 and a beta of 0.87. DaVita Inc. has a fifty-two week low of $101.00 and a fifty-two week high of $247.49. The firm has a 50-day simple moving average of $182.52 and a two-hundred day simple moving average of $178.61.

DaVita (NYSE:DVA) last issued its earnings results on Thursday, October 29th. The company reported $3.82 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.57 by $0.25. The firm had revenue of $3.58 billion for the quarter, compared to the consensus estimate of $3.52 billion. DaVita had a net margin of 6.49% and a negative return on equity of 225.93%. The business’s revenue was up 4.6% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.51 earnings per share. On average, equities research analysts predict that DaVita Inc. will post 14.66 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts have commented on DVA shares. Weiss Ratings raised DaVita from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Friday, October 9th. Deutsche Bank Aktiengesellschaft restated a “buy” rating and set a $265.00 target price on shares of DaVita in a report on Wednesday, August 5th. Raymond James Financial set a $220.00 target price on shares of DaVita in a research report on Friday, August 7th. Barclays decreased their price target on shares of DaVita from $224.00 to $216.00 and set an “equal weight” rating for the company in a research note on Monday, November 2nd. Finally, UBS Group lifted their price target on shares of DaVita from $270.00 to $287.00 and gave the company a “buy” rating in a research report on Monday, November 2nd. Four research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, DaVita currently has a consensus rating of “Moderate Buy” and an average price target of $235.86.

DaVita Profile

DaVita Inc is a healthcare provider focused on kidney care. Its core business is operating outpatient dialysis centers that provide treatment and related services to people with chronic kidney failure.

The company also offers home dialysis programs, provides dialysis services to patients in hospitals, and supports kidney care through services such as care coordination and education. DaVita primarily serves patients in the United States and also operates in international markets.

Founded in 1994 as Total Renal Care, the company adopted the name DaVita in 2000.